<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

2 min read

SmartTRAK Experts Take the Stage at MNVC 2023

By Thomas Wallick on 11/14/23 9:30 AM

SmartTRAK's Elise Wolf, Vice President and General Manager of Orthopedics, Digital and Quality, along with Beth Roach, Director, Data Strategy, will be discussing new trends in Ambulatory Surgical Centers (ASC) and effective targeting strategies at the 2023 Musculoskeletal New Ventures Conference (MNVC) on Nov 14-15 at the FedEx Institute of Technology in Memphis, TN. They will also delve into a detailed case study on ASC builds. Their presentation is titled "Targeting the ASC: Essential Knowledge for Orthopedic Companies." Make sure you don’t miss out on Elise and Beth's expert insights!

Topics: Orthopedics
Continue Reading
3 min read

Anika's Expanding Shoulder Preservation Solutions

By Lisa Mahan on 10/31/23 9:33 AM

Anika’s President and CEO Cheryl Blanchard, Ph.D., discusses the Company’s expanding portfolio of shoulder preservation solutions

Anika Therapeutics entered the Reverse Shoulder Market this year with the US market release of the RevoMotion Reverse Shoulder Arthroplasty System, expanding their complement of products for shoulder joint preservation and replacement. This new offering allows the Company to compete in the rapidly growing US Market for Reverse Shoulders. Lisa Mahan, SmartTRAK Senior Analyst Total Joints & Extremities, talked with Cheryl Blanchard, PhD, President and CEO of Anika, to discuss the launch of RevoMotion, along with the X-Twist Fixation System, Integrity Patch System, Cingal next generation OA injectable and Tactoset Injectable Bone Substitute.
 
The Interview
 

SmartTRAK: RevoMotion has been out almost nine months now in limited release and you just went to full market release. Congratulations. How is that going?

Cheryl Blanchard: Thank you! Anika announced the full market release of the RevoMotion Reverse Shoulder Arthroplasty System (RSA) during the 2023 Orthopaedic Summit (OSET) Annual Meeting September 20-23 in Boston, MA and the response has been overwhelmingly positive.

We began the limited launch in January 2023 and have performed over 100 cases since then. The feedback we received and the response during the limited market release was impressive as some of the first patients in have already returned to their surgeons and asked for the same implant to be placed in their other shoulder. To have patients far enough into recovery to want the RevoMotion RSA in their other shoulder says a lot about the system and its future success. The limited release allowed us to collect feedback to better optimize the instrumentation and surgical technique for the full market release as well. Though we finished gathering feedback months ago, manufacturing instrument sets and system components takes time. That brought us right to our full market release during OSET in September.

We know that the reverse shoulder market is a crowded space. Given that probably 80% of the market is reverse shoulders, for Anika we knew we had something incredible to offer clinicians and patients based on the historic Arthrosurface design philosophies focused on bone sparing, motion preservation and anatomic design features. We also knew that with the data-backed and trusted OVOMotion with Inlay Glenoid Total Shoulder Arthroplasty System, it would be difficult to penetrate the full shoulder arthroplasty market without having a reverse option.

Additionally, there is a big shift of a lot of these products and procedures into the ASC setting. We will possibly see even more products coming into the ASC when CMS changes how they reimburse and we realized that there was a real opportunity to provide optimized instrument trays that would reduce the operating room footprint. RevoMotion has a two-tray instrumentation system that is very streamlined. The surgical technique is also very streamlined. We're hearing great feedback on it and we're excited to be in full market release coming into the fourth quarter.

That's wonderful. You mentioned the instrument trays and some of the design. If there was one thing that differentiates RevoMotion from other reverse shoulders on the market, what would you say that is?

CB:We believe and continue to hear feedback from surgeon users that having the smallest threaded glenoid base plate on the market is one of the biggest differentiators. Personally, I didn't understand the true significance of that until I started to speak directly with surgeons who had used the system. Listening to real-time feedback and observing in the OR, you realize it's a major benefit as it provides...

To download and read the complete transcript of the interview with Anika’s President & CEO Cheryl Blanchard conducted by Lisa Mahan, VP Product Development & IT, Sr. Analyst TJ&E, just click the button below. Download the Transcript

Continue Reading
4 min read

SmartTRAK Announces Software Advancements & Launches Insights Reports for Emerging Orthopedic/Spine and Wound Medtech Markets

By Gabriele Nichols on 10/18/23 10:15 AM

New SaaS technology offering delivers competitive advantage in rapidly changing Ambulatory Surgery Center market.

SmartTRAK, the leading global Medtech business and market software intelligence solution in the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets, announces the release of enhanced software products and strategic reports available for purchase in Q4 to help clients position themselves for growth in 2024 and beyond.

Powered by industry experts and data analysts, SmartTRAK's Insights-as-a-Service platform is the Medtech industry's only "all-in-one" solution that delivers market insights and business intelligence via an intuitive SaaS platform. Designed to reduce the redundancies in market research, SmartTRAK compiles and curates insights from hundreds of disparate information sources into its highly valued SmartTRAK Daily Updates, comprehensive market overviews and simple-to-use tools and dashboards for market, product and financial analysis.

Continue Reading
1 min read

Trends Potentially Impacting the Total Joints Market: A Flash Report

By Lisa Mahan on 10/18/23 8:03 AM

SmartTRAK takes a quick look at recent trends that may influence the Total Joints Market in the near and long term

Wall Street Analysts recently called out two trends specifically that could influence the Total Joints Market. One trend, the strengthening of the US dollar, is likely to impact the global market in 2024. Another trend is the increased prescribing of GLP-1 drugs, such as Ozempic, Wegovy, Byetta and Mounjaro, medications first used to treat Type 2 diabetes, as a treatment for obesity. This has the potential to impact the market down the road. In this downloadable article, SmartTRAK maps out the potential impact of these trends.

To download and read the complete article by SmartTRAK's Lisa Mahan, Product Development & IT, Sr. Analyst TJ&E, just click the button below. Read the Article

Continue Reading
3 min read

Statera Medical: Smart Shoulder Implant - An Interview with Samuel Bourdon

By Nick Fitzpatrick on 8/11/23 11:46 AM

Samuel Bourdon, Co-Founder and Chief Executive Officer of Statera Medical discusses Statera Medical’s development of a smart shoulder implant.

In an interview withSmartTRAK,Samuel Bourdon, the Co-Founder and Chief Executive Officer of Statera Medical, discusses how Statera Medical came to be, why their focused on creating a smart implant for the shoulder arthroplasty market and where he sees the Company going in the future.

To find out more, including the design rationale behind Statera’s smart shoulder ecosystem and how Statera fits in the shoulder arthroplasty market, click on the following video to listen to the full interview (29:25). If you would like to download the complete transcript of the interview, click here.


SmartTRAK: Hey guys, this is Nick with SmartTRAK. I'm here with Samuel Bourdon, CEO and founder of Statera Medical. I appreciate you joining me this morning and doing this interview. Samuel, can you give us an introduction about your yourself and a brief background of your experience in the orthopedics industry?


Samuel Bourdon: I'm a mechanical engineer by training. I have worked in product development since 2012 and mostly in the aerospace and recreational product. And when I turned 30, I quit my job and decided to go back to school to do a full-time master degree in biomedical engineering. And then I managed to do a master in business administration part-time during the same period. So before Statera Medical I had no experience in orthopedic industry at all, so it's a first time for me.

That's definitely monumental. Why'd you switch from aerospace to biomedical?

SB: Yeah, I just hit a bigger why in my career and I wanted to put a human at the center of it, so that's what made me took that decision.

Where did you get your master's in biomed from?

SB: From Polytechnique Montreal. It's the same university I got my mechanical engineer degree.

Let's dive into the company that you founded, Statera Medical. So what was the inspiration behind founding Statera Medical, and what's your mission statement behind it?

SB: What happened is I met another engineer and an orthopedic surgeon, and it was really all about reducing complication rates and improving patient outcomes, which ultimately results in ...

To download the complete transcript of SmartTRAK's interview with Samuel Bourdon, the Co-Founder and CEO of Statera Medical, just click the button below. Download the Transcript

Continue Reading
2 min read

ArthroFree: The Surgical Camera for the Wireless Era

By Andy Knapik on 8/2/23 3:39 PM

In a joint interview with Eugene Malinskiy, founder and CEO of Lazurite, and orthopedic surgeon Dr James Voos, we discuss the world’s first wireless surgical camera, the Lazurite ArthroFree camera.

Eugene Malinskiy, the founder and CEO of Lazurite, and orthopedic surgeon Dr. James Voos discuss the technological and clinical benefits of the new ArthroFree camera, the world’s first fully wireless surgical camera, with Andy Knapik, SmartTRAK's Senior Analyst, Soft Tissue & Arthroscopic Technologies.

To learn more about Lazurite and the ArthroFree System, click the following video to watch the interview (27:05 min).  For more details, interview topics by timecode are provided below. To download a complete transcript of the interview, click here.

 

Interview Topics By Timecode

1:25 Background of Lazurite and the ArthroFree camera.

7:05 Surgeon impressions of the ArthroFree camera.

10:10 Camera integration, image quality, battery life, ergonomics.

16:05 How the camera connects to the monitor and image capture.

19:22 How do facilities react to purchasing the ArthroFree.

22:05 Uses of the ArthroFree camera.

To download the complete transcript of the interview with Eugene Malinskiy, the founder and CEO of Lazurite, and orthopedic surgeon Dr. James Voos, just click the button below. Download the Transcript

Continue Reading
2 min read

Healthy Growth: Q123 Trauma Market Recap

By Natasha Weeks on 7/24/23 9:28 AM

Strong returns in IM Nailing and a flurry of activity in the Pediatric space results in a healthy Q123 for the Trauma Market

The US Trauma Market grew +6.0% in Q123 fueled by new product adoption. While headwinds such as supply chain constraints, economic challenges and staffing shortages could darken the forecast, SmartTRAK expects the Trauma Market will not be as heavily impacted as its elective procedure counterparts and should continue to experience healthy growth through 2023 as many manufacturers note Q1 results are in line with pre-Covid historical trends.
 
Among the many topics covered in detail in SmartTRAK 's comprehensive Q123 Trauma Market Recap *  are:
  • Complete Q123 Trauma Market Overview
  • SmartTRAK's Expert Market Analysis and Insights
  • All Trauma Companies' News, Revenues, Data, Charts and Market Shares
  • IM Nailing Closes the Quarter on High with Solid Returns
  • New Regulatory Clearances Propel the Pediatric Trauma Segment:
    • OrthoPediatrics
    • NuVasive Specialized Orthopedics, Inc.
    • Wishbone Medical
  • Q123 Trauma Regulatory Highlights

During Q1, the Pediatric Trauma segment experienced a notable surge in regulatory clearances, indicating forthcoming product launches aimed at bolstering the segment's growth. These approvals signal  ...

Read the entire Q123 Trauma Market Recap, including SmartTRAK's expert analysis, news, data, charts, revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below. Learn More about Subscribing to SmartTRAK


Continue Reading
2 min read

Mergers & Acquisitions: Q123 Spine Market Recap

By Courtney Sheedy on 7/14/23 2:05 PM

Despite M&A uncertainties with Orthofix/SeaSpine and Globus/NuVasive, the Spine market posted strong growth for Q123.

Q123 gave definition to some of the merger and acquisition uncertainty, but there’s undoubtedly more to be revealed as 2023 presses on. Only a crystal ball could predict the full-year performance of the newly integrated Orthofix/SeaSpine plus the highly-anticipated combination of Globus with NuVasive (many others on the horizon), yet the Spine market posted strong growth in Q123 amidst the disruption.
 

Among the many topics covered in detail in SmartTRAK's comprehensive Q123 Spine Market Recap* are:

  • Complete Q123 Spine Market Overview
  • SmartTRAK's Expert Market Analysis and Insights
  • All Spine Companies' News, Revenues, Data, Charts and Market Shares
  • Top Players' Performance
    •  JNJ/DePuy Synthes
    • Globus 
    • NuVasive 
    • Stryker
  • Q123 Spine Trends
    • M&A Activity
    • New Products
    • Reimbursement Dynamics
  • Regulatory Highlights
  • Europe Regulatory Updates
  • Clinical Study Progress

Orthofix and SeaSpine announced the completion of its merger in Q123 in which SeaSpine became a wholly owned subsidiary of Orthofix. In a recent note, Canaccord Genuity highlighted SeaSpine7D Surgical and Simplify as the most notable of the recent spine acquisitions. SmartTRAK agrees and notes that ...

Read the entire Q123 Spine Market Recap, including SmartTRAK's expert analysis, news, data, charts, revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below. Learn More about Subscribing to SmartTRAK

Continue Reading
2 min read

Advancements and Innovations In Bio-Integrative Fixation: An Interview with Orahn Preiss-Bloom

By Andy Knapik on 7/13/23 9:48 AM

Orahn Preiss-Bloom, founder and Chief Innovation Officer of Ossio Ltd. discusses Osssio’s advancements in innovations in the world of bio-integrative fixation devices.

In an interview with SmartTRAK, Orahn Preiss-Bloom, the founder and Chief Innovation Officer of Ossio Ltd, discusses how Ossio came to be, what makes their products different and where he sees the Company going in the future.

To find out more about Ossio, click on the following video to watch the interview (24:42 min). To download a complete transcript of the interview, click here. For more details, interview topics by timecode are provided below.

Interview Topics By Timecode

00:44 Orahn’s background in the medical industry.
03:53 What differentiates the OSSIO product.
07:55 Initial uses for OSSIOfiber.
12:40 Overcoming surgeon objections to biointegrative materials.
15:13 Ossio education labs.
19:44 Ossio in sports medicine.
22:41 Surgeon concerns.

To download the complete transcript of the interview with Orahn Preiss-Bloom, Founder and Chief Innovation Officer of Ossio Ltd, just click the button below. Download the Interview Transcript

Continue Reading
3 min read

Setting the Stage for Growth: Q123 Ortho Enabling Tech Market Recap

By Shelly Caruso on 6/26/23 10:19 AM

Continued strength in ortho robotics placements and a crowd of new product launches in Q123 set the stage for growth in the remainder of the year.

The Q123 US Ortho Enabling Tech Market declined slightly by -0.6% YoY according to SmartTRAK Financial Dashboard . Stryker* (SYK) remained the market leader with 55.6% share, followed by Smith+Nephew* ( SNN), Zimmer Biomet* (ZBH) and DePuy Synthes* (JNJ). For detailed Q132 revenues and shares by company in the US, EU and ROW, see SmartTRAK Ortho Enabling Tech Financial Dashboard .


Among the many topics covered in detail in SmartTRAK's comprehensive Q123 Ortho Enabling Tech Market Recap* are:

  • Complete Q123 Otho Enabling Tech Market Overview
  • SmartTRAK's Expert Market Analysis and Insights
  • All US Ortho Enabling Tech Companies' News, Revenues, Data, Charts and Market Shares
  • Robust Q123 Robotics Performances by Company
    • Stryker
    • Zimmer Biomet
    • Smith+Nephew
    • JNJ/Depuy Synthes
  • New Product Introductions
    • Robotics and Ecosystem Launches
    • Navigation and Planning Innovations
  • SmartTRAK's Selected Highlights from Q123 Conferences
    • JP Morgan 41st Annual Healthcare Conference
    • Canaccord Genuity 2023 Musculoskeletal Conference
    • AAOS 2023 Annual Meeting

In an International Society for Technology in Arthroplasty (ISTA) presentation at the American Academy of Orthopaedic Surgeons 2023 (AAOS 2023) Annual Meeting, President, Digital, Robotics and Enabling Technology at SYK Robert Cohen discussed innovations including a fully connected operating room for a common user experience with planning and mixed-reality guidance combined with robotics and data transfer capabilities. Enabling technology continues to see adoption and integration in orthopedics and with it, the introduction of ...

Read the entire Q123 Ortho Enabling Tech Market Recap, including SmartTRAK's expert analysis, news, data, charts, company revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.Learn More about Subscribing to SmartTRAK

Continue Reading
  • There are no suggestions because the search field is empty.

Follow Us on Social Media

Recent Articles